课题基金 / 基金详情

A Rugged, Reliable, Portable, Safe, and Simple Naloxone HCl Auto-Injector forLife-Saving Treatment of Opioid Overdose

A Rugged, Reliable, Portable, Safe, and Simple Naloxone HCl Auto-Injector forLife-Saving Treatment of Opioid Overdose
坚固、可靠、便携式、安全且简单的盐酸纳洛酮自动注射器,用于挽救阿片类药物过量的生命治疗
批准号:
10764158
负责人:
Conor R Cullinane
金额:
$32.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-01 至 2024-07-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary From 2019 to 2020, overdose deaths in the US increased by 30% year on year; 187 people die each day from opioid overdose in the US. Naloxone has significantly decreased opioid mortality with increased usage as a first line life-saving measure prior to emergency help and hospitalization. Naloxone HCl Injection, USP (Naloxone) is an opioid antagonist that rapidly reverses overdose and quickly restores normal breathing. It can be given to any person showing signs of an overdose. There is no potential for abuse/addiction to Naloxone. The drug is low cost, available across all 50 states, often without a prescription. Ambulances and hospitals have Naloxone on hand, and medical staff trained to administer it; however, a call for help or trip to the ER is often too late. At least 40% of the time, life-saving treatment for opioid overdose is administered by an untrained bystander, often under situations of extreme stress. The benefits of Naloxone for reversing the effects of opioid overdose have been demonstrated conclusively. The most pressing question today then is what method of administration of Naloxone is most efficacious for untrained bystanders. Studies show that Auto-Injectors (AIJ) offer the best combination of low cost, safety, reliability, ergonomic design, and most of all rapid fail-safe injection of Naloxone. Towards this end, Pirouette Medical has developed a novel and proprietary AIJ platform, based on a previous AIJ QUICPUSH for epinephrine injections, that can be adapted to safely deliver intramuscular Naloxone injections correctly and easily. Our Naloxone Auto-Injector (NAIJ), REZQGO, is a low-profile, disk-shaped, injection device with a patient-centric focus on affordability, portability, and usability. Its intuitive design allows individuals with limited or no training to easily administer an injection to themselves or others. The AIJs physical design allows for simple and stress-free self-administration, minimizing the risk of inadvertent administration, lacerations, needle sticks, or other injuries. The device can safely and effectively inject life-saving drugs through various clothing materials. Finally, the REZQGO design is versatile and can be adjusted to accommodate a wide variety of volumes and other parameter changes such as dose delivered and needle injection depth for future drug pairings. In Phase I we will rigorously verify the design and usability of a non-GMP prototype(s) of our REZQGO auto- injector. In Phase II the goal will be to manufacture three GMP registration batches, complete the full set of design validation tests, and submit an NDA to the FDA for regulatory approval via the 505(b)(2) pathway, using QUICPUSH and other commercially available AIJ projects as predicate devices. Overall, this project will help bring to market a novel low-cost device that anyone could use to safely deliver lifesaving Naloxone HCL Injection, USP intramuscularly during an opioid overdose.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金